和黃醫藥(00013.HK)自身免疫性疾病藥物於中國啟動II/III期臨床試驗
和黃醫藥(00013.HK)公布,在中國啟動一項索樂匹尼布用於治療成人溫抗體型自身免疫性溶血性貧血(wAIHA)的II/III期臨床試驗。wAIHA是一種可導致貧血的自身免疫性疾病,治療選擇非常有限。首名患者已於2022年9月30日接受首次給藥治療。
該項研究是一項隨機、雙盲、安慰劑對照的臨床試驗。研究的II期部分旨在評估索樂匹尼布治療成人wAIHA患者的安全性和初步療效。若II期研究部分取得積極的結果,則將啟動III期研究部分以確認該療法的療效及安全性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.